Protagonist Therapeutics Inc (NASDAQ:PTGX) price on Friday, February 28, rose 3.44% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $37.59.
A look at the stock’s price movement, the close in the last trading session was $36.34. The PE ratio in trailing twelve months stood at 8.94. Turning to its 52-week performance, $48.89 and $24.22 were the 52-week high and 52-week low respectively. Overall, PTGX moved -1.62% over the past month.
Protagonist Therapeutics Inc’s market cap currently stands at around $2.31 billion, with investors looking forward to this quarter’s earnings report slated for in April.
The average forecast suggests down to a -87.22% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 93.7M, representing a -78.43% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PTGX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend PTGX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PTGX’s current price about -0.05% and -1.52% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.56, while 7-day volatility ratio is 6.03% and 4.22% in the 30-day chart. Further, Protagonist Therapeutics Inc (PTGX) has a beta value of 2.33, and an average true range (ATR) of 1.66. Analysts have given the company’s stock an average 52-week price target of $60, forecast between a low of $50 and high of $62. Looking at the price targets, the low is -33.01% off current price level while to achieve the yearly target high, price needs to move -64.94%. Nonetheless, investors will most likely welcome a -59.62% jump to $60 which is the analysts’ median price.
If we refocus on Protagonist Therapeutics Inc (NASDAQ:PTGX), historical trading data shows that trading volumes averaged 630.80K over the past 3 months. The company’s latest data on shares outstanding shows there are 61.04 million shares.
The 5.85% of Protagonist Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 100.49% of the company’s shares. Current price change has pushed the stock -2.62% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PTGX stock continues to rise going into the next quarter.
